SCM
ADCT icon

Suvretta Capital Management’s ADC Therapeutics ADCT Stock Holding History

Suvretta Capital Management’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-175,090
Closed -$8.2M – 96
2020
Q2 		$8.2M Buy
+175,090
New +$6.65M 0.18% 52

Other funds holding ADCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
GH
Grosvenor Holdings Chicago, Illinois $512M AUM 19.57% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Suvretta Capital Management's ADCT Position: Q3 2020 in Review

Suvretta Capital Management sold out of ADC Therapeutics (ADCT) in Q3 2020, closing a stake of 175,090 shares — an estimated $8.2M sold.

Suvretta Capital Management first reported a position in ADCT in Q2 2020 and held it in 1 quarter. The position peaked at $8.2M in Q2 2020. 52 funds tracked by Wall St. Rank hold ADCT as of Q3 2020.

  • Suvretta Capital Management reported no remaining ADC Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Suvretta Capital Management sold 175,090 ADC Therapeutics shares in Q3 2020, an estimated $8.2M.
  • Suvretta Capital Management first reported a position in ADC Therapeutics in Q2 2020 and held it in 1 quarter.
  • Suvretta Capital Management's ADC Therapeutics position peaked at $8.2M in Q2 2020.
  • 52 funds tracked by Wall St. Rank held ADC Therapeutics as of Q3 2020.

Based on Suvretta Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.